BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 16257398)

  • 1. Inhibition of acetylcholinesterase by the anticancer prodrug CPT-11.
    Hyatt JL; Tsurkan L; Morton CL; Yoon KJ; Harel M; Brumshtein B; Silman I; Sussman JL; Wadkins RM; Potter PM
    Chem Biol Interact; 2005 Dec; 157-158():247-52. PubMed ID: 16257398
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The crystal structure of the complex of the anticancer prodrug 7-ethyl-10-[4-(1-piperidino)-1-piperidino]-carbonyloxycamptothecin (CPT-11) with Torpedo californica acetylcholinesterase provides a molecular explanation for its cholinergic action.
    Harel M; Hyatt JL; Brumshtein B; Morton CL; Yoon KJ; Wadkins RM; Silman I; Sussman JL; Potter PM
    Mol Pharmacol; 2005 Jun; 67(6):1874-81. PubMed ID: 15772291
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The 3D structure of the anticancer prodrug CPT-11 with Torpedo californica acetylcholinesterase rationalizes its inhibitory action on AChE and its hydrolysis by butyrylcholinesterase and carboxylesterase.
    Harel M; Hyatt JL; Brumshtein B; Morton CL; Wadkins RM; Silman I; Sussman JL; Potter PM
    Chem Biol Interact; 2005 Dec; 157-158():153-7. PubMed ID: 16289500
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The inhibition of acetylcholinesterase by irinotecan and related camptothecins: key structural properties and experimental variables.
    Dodds HM; Hanrahan J; Rivory LR
    Anticancer Drug Des; 2001; 16(4-5):239-46. PubMed ID: 12049482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The anticancer prodrug CPT-11 is a potent inhibitor of acetylcholinesterase but is rapidly catalyzed to SN-38 by butyrylcholinesterase.
    Morton CL; Wadkins RM; Danks MK; Potter PM
    Cancer Res; 1999 Apr; 59(7):1458-63. PubMed ID: 10197614
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The mechanism for the inhibition of acetylcholinesterases by irinotecan (CPT-11).
    Dodds HM; Rivory LP
    Mol Pharmacol; 1999 Dec; 56(6):1346-53. PubMed ID: 10570064
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activation of a camptothecin prodrug by specific carboxylesterases as predicted by quantitative structure-activity relationship and molecular docking studies.
    Yoon KJ; Krull EJ; Morton CL; Bornmann WG; Lee RE; Potter PM; Danks MK
    Mol Cancer Ther; 2003 Nov; 2(11):1171-81. PubMed ID: 14617791
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and biological evaluation of novel A-ring modified hexacyclic camptothecin analogues.
    Kim DK; Ryu DH; Lee JY; Lee N; Kim YW; Kim JS; Chang K; Im GJ; Kim TK; Choi WS
    J Med Chem; 2001 May; 44(10):1594-602. PubMed ID: 11334569
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification and properties of a major plasma metabolite of irinotecan (CPT-11) isolated from the plasma of patients.
    Rivory LP; Riou JF; Haaz MC; Sable S; Vuilhorgne M; Commerçon A; Pond SM; Robert J
    Cancer Res; 1996 Aug; 56(16):3689-94. PubMed ID: 8706009
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antitumor potential of a novel camptothecin derivative, ZBH-ZM-06.
    Wu D; Zhao DW; Li YQ; Shi WG; Yin QL; Tu ZK; Yu YY; Zhong BH; Yu H; Bao WG
    Oncol Rep; 2018 Feb; 39(2):871-879. PubMed ID: 29251321
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hydrolysis of irinotecan and its oxidative metabolites, 7-ethyl-10-[4-N-(5-aminopentanoic acid)-1-piperidino] carbonyloxycamptothecin and 7-ethyl-10-[4-(1-piperidino)-1-amino]-carbonyloxycamptothecin, by human carboxylesterases CES1A1, CES2, and a newly expressed carboxylesterase isoenzyme, CES3.
    Sanghani SP; Quinney SK; Fredenburg TB; Davis WI; Murry DJ; Bosron WF
    Drug Metab Dispos; 2004 May; 32(5):505-11. PubMed ID: 15100172
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibitory activity of camptothecin derivatives against acetylcholinesterase in dogs and their binding activity to acetylcholine receptors in rats.
    Kawato Y; Sekiguchi M; Akahane K; Tsutomi Y; Hirota Y; Kuga H; Suzuki W; Hakusui H; Sato K
    J Pharm Pharmacol; 1993 May; 45(5):444-8. PubMed ID: 8099964
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural constraints affect the metabolism of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) by carboxylesterases.
    Wadkins RM; Morton CL; Weeks JK; Oliver L; Wierdl M; Danks MK; Potter PM
    Mol Pharmacol; 2001 Aug; 60(2):355-62. PubMed ID: 11455023
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of HI-6 oxime: potential use in protection of human acetylcholinesterase inhibited by antineoplastic drug irinotecan and its cyto/genotoxicity in vitro.
    Radić B; Vrdoljak AL; Zeljezić D; Fuchs N; Berend S; Kopjar N
    Acta Biochim Pol; 2007; 54(3):583-93. PubMed ID: 17713603
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and evaluation of 4-substituted coumarins as novel acetylcholinesterase inhibitors.
    Razavi SF; Khoobi M; Nadri H; Sakhteman A; Moradi A; Emami S; Foroumadi A; Shafiee A
    Eur J Med Chem; 2013 Jun; 64():252-9. PubMed ID: 23644208
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis, cytotoxicity and molecular modelling studies of new phenylcinnamide derivatives as potent inhibitors of cholinesterases.
    Saeed A; Mahesar PA; Zaib S; Khan MS; Matin A; Shahid M; Iqbal J
    Eur J Med Chem; 2014 May; 78():43-53. PubMed ID: 24675179
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of novel selective inhibitors of human intestinal carboxylesterase for the amelioration of irinotecan-induced diarrhea: synthesis, quantitative structure-activity relationship analysis, and biological activity.
    Wadkins RM; Hyatt JL; Yoon KJ; Morton CL; Lee RE; Damodaran K; Beroza P; Danks MK; Potter PM
    Mol Pharmacol; 2004 Jun; 65(6):1336-43. PubMed ID: 15155827
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural modifications of 4-aryl-4-oxo-2-aminylbutanamides and their acetyl- and butyrylcholinesterase inhibitory activity. Investigation of AChE-ligand interactions by docking calculations and molecular dynamics simulations.
    Vitorović-Todorović MD; Koukoulitsa C; Juranić IO; Mandić LM; Drakulić BJ
    Eur J Med Chem; 2014 Jun; 81():158-75. PubMed ID: 24836068
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, synthesis and pharmacological evaluation of chalcone derivatives as acetylcholinesterase inhibitors.
    Liu HR; Liu XJ; Fan HQ; Tang JJ; Gao XH; Liu WK
    Bioorg Med Chem; 2014 Nov; 22(21):6124-33. PubMed ID: 25260958
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel coumarin-3-carboxamides bearing N-benzylpiperidine moiety as potent acetylcholinesterase inhibitors.
    Asadipour A; Alipour M; Jafari M; Khoobi M; Emami S; Nadri H; Sakhteman A; Moradi A; Sheibani V; Homayouni Moghadam F; Shafiee A; Foroumadi A
    Eur J Med Chem; 2013; 70():623-30. PubMed ID: 24211638
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.